OncoMatch/Clinical Trials/NCT04776330
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Is NCT04776330 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies BCMA targeted prime CAR-T cells for multiple myeloma.
Treatment: BCMA targeted prime CAR-T cells — This is a single arm study to evaluate the efficacy and safety of BCMA-targeted prime CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA expression (cell membrane expression)
Evidence for cell membrane BCMA expression
Demographics
Lab requirements
Kidney function
creatinine clearance≤2 x ULN
Liver function
ALT/AST≤3 x ULN and bilirubin≤2 x ULN
Cardiac function
Left ventricular ejection fraction ≥50%
Left ventricular ejection fraction ≥50%; Sufficient hepatic function defined by ALT/AST≤3 x ULN and bilirubin≤2 x ULN; Sufficient renal function defined by creatinine clearance≤2 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04776330 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require BCMA?
Yes, BCMA expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages